Introduction 65
Expansion of the PFC in Old World anthropoid primates (Catarrhini) is associated with derived 66 characteristics such as increased dendritic complexity and synaptic spines of the glutamatergic 67 excitatory projection (pyramidal) neurons compared to more posterior cortical association and 68 sensory areas, creating an anterior-posterior gradient of synaptic density [28] [29] [30] . Moreover, this 69 gradient is exaggerated in humans by the disproportionately high number of spines on 70 pyramidal neurons in the human PFC, as compared to other analyzed primates 5 . The anterior-71 posterior gradient of early neocortical synaptogenesis begins during the human mid-fetal period 72 or equivalent developmental age in other mammals 7,31 , before proceeding in an anterior-73 posterior direction 32 and continues at an accelerated rate well beyond birth 33, 34 . Identifying the 74 genetic basis and molecular mechanisms underlying this anterior-posterior gradient of 75 synaptogenesis may provide clues to the origin of increased synaptic density within the human 76 PFC and some aspects of human uniqueness, cognition, and neuropsychiatric disease. In our 77 accompanying study 35 , we identified a prefrontal-enriched gradient of retinoic acid (RA) 78 concentration and pattern of gene expression in the human mid-fetal neocortex. Among the 79 identified genes were those linked to synaptogenesis, including CBLN2, which had the greatest 80 loading of differentially expressed genes representing the anterior-posterior neocortical axis, 81
and was upregulated in the mid-fetal PFC compared to the prospective primary motor cortex 82 (M1C) and other non-PFC areas 35 . Thus, we hypothesize that RA-mediated regulation of 83 CBLN2 expression in the human mid-fetal PFC underlies the disproportionate number of 84 synapses in the PFC. 85 86
Species-specific enrichment and laminar pattern of CBLN2 expression in mid-fetal PFC 87
Members of the CBLN family encode secreted neuronal glycoproteins, which serve as excitatory 88 and inhibitory synaptic organizing molecules [21] [22] [23] [24] [25] [26] [27] . CBLN2, along with its binding partners, the 89 neurexin (NRXN) family of cell adhesion proteins and the glutamate receptor delta (GRID/GluD) 90 receptors [23] [24] [25] [26] [27] , have been implicated in various neuropsychiatric diseases including autism 91 spectrum disorders (ASD), schizophrenia, Tourette's syndrome, and obsessive-compulsive 92 disorder (OCD) [36] [37] [38] [39] . By analyzing RNA-sequencing (RNA-seq) transcriptomic data from eleven 93 neocortical areas of the human and macaque brain across prenatal and postnatal development 94 from the BrainSpan and PsychENCODE projects 15,20 (brainspan.org and 95 evolution.psychencode.org), we identified a precocious and transient increase in human (1.8-96 fold change) and macaque (2.0-fold change) CBLN2 expression in the major areas of the 97 prospective PFC (i.e., medial, mPFC/MFC; dorsolateral, dlPFC/DFC; ventrolateral, vlPFC/VFC; 98 and orbital, oPFC/OFC) compared to the seven analyzed non-PFC areas during mid-fetal 99 development (13-24 postconception weeks, PCW) or periods 4-6 according to Kang et al. 40 100 (Student's t-test, human P = 2.2e-16; macaque P = 1.7e-9; Fig. 1a ) 20 . Both human and 101 macaque CBLN2 levels increase during mid-fetal periods in parallel with key genes associated 102 with synapse and dendrite development (Extended Data Fig. 1 ), suggesting a connection 103 between the two events. Around the time of late infancy, both human and macaque CBLN2 104 expression levels are comparable across analyzed neocortical areas, despite modest but 105 statistically significant increased expression in PFC areas compared to non-PFC areas (Human: 106 periods 7-10: 1.2-foldchange, periods 11-14: 1.1-foldchange; Macaque: periods 7-10: 1.25-107 foldchange, periods 11-14: 1.2-foldchange; Fig. 1a) . Furthermore, the level of CBLN2 108 expression is greater and the maximum expression occurs comparatively earlier in human PFC, 109 compared to macaque PFC during mid-fetal periods (Student's t-test, P < 0.005 at mid-fetal 110 ages; Not significant during later fetal development to adult ages; Fig. 1a Fig. 2) . We also analyzed the spatio-120 temporal expression profiles of the genes encoding the binding partners of the CBLN family 121 members, NRXN1,2,3 and GRID1,2. While none of these genes showed a distinct PFC 122 upregulation during mid-fetal development, all were expressed in the PFC and most showed 123 increasing levels of expression throughout development (Extended Data Fig. 1) . 124
Previous studies have reported an anterior-posterior gradient of CBLN2 expression in 125 the human mid-fetal neocortex, with upregulated expression specifically in the PFC 18,41 . These 126 studies also showed that CBLN2 was detected both in neurons of prospective upper (layers 2 127 to 4) and deeper layers (layers 5 and 6) of the human PFC, but only faintly in the more posterior 128 mid-fetal neocortex. We confirmed this finding with close re-examination of CBLN2 expression 129 in the mid-fetal human PFC (21, 22 PCW; N = 2 brains), using in situ hybridization ( Fig. 1b) . 130 We also identified an anterior-posterior gradient of Cbln2 expression in macaque (114, 110 131 PCD; N = 2 brains) and mouse (P0; N = 4 brains) at equivalent developmental ages ( Fig. 1b) . 132
Interestingly, in mid-fetal macaque, Cbln2 expression was mostly observed in the upper cortical 133 plate corresponding to the prospective upper layers with noticeably weaker expression in the 134 deeper layers (Fig. 1b) . In neonatal mice, Cbln2 was restricted to the prospective upper-layers 135 ( Fig. 1b) . Together, CBLN2 expression displayed a progressive extension into the deeper 136 layers of the mid-fetal PFC in humans compared to macaques, and in macaques compared to 137 mice. 138 139 Hominini-specific deletions in a retinoic acid-responsive CBLN2 enhancer acting in the 140
mid-fetal PFC 141
In order to understand the spatial and laminar regulatory mechanism of CBLN2 expression in 142 the mid-fetal PFC, we analyzed publicly available datasets on the regulatory landscape of the 143 developing and adult mouse and human brains generated by the ENCODE and PsychENCODE 144 projects 20,42 . Analyzing the mouse Cbln2 locus we identified three putative cis-regulatory 145 elements marked as DNase 1 hypersensitive sites, which we designated as Cbln2 enhancer 1 146 (Cbln2 E1, 1452 bp), Cbln2 enhancer 2 (Cbln2 E2, 1005 bp), and Cbln2 promoter (Cbln2 Pro, 147 316 bp; Fig. 1c, top) . The sequences of these putative cis-regulatory elements are moderately 148 conserved between mouse and human (E1, 76.3%; E2, 84.3%; and Pro, 70.0%). Of note, 149 mouse Cbln2 E2 showed DNase 1 hypersensitivity peaks only in 14.5 postconception days 150 (PCD) samples and Cbln2 E1 only in 8 postnatal weeks samples ( Fig. 1c, top) . Analysis of 151 genomic sites with differential distribution of H3K27ac, a mark of active enhancers, in the 152 developing and adult human dlPFC indicates that CBLN2 Pro is active at all three analyzed time 153 points (i.e., mid-fetal, early infancy and adult ages), while CBLN2 E1 is active during mid-fetal 154 age and infancy, and CBLN2 E2 is only active during mid-fetal age (Fig 1c, bottom) . 155
We next assessed the activity of these putative regulatory regions using transgenic 156 mouse lines in which a lacZ expression cassette was placed downstream of mouse Cbln2 E1, 157
Cbln2 E2, or Cbln2 Pro. While Cbln2 E1-lacZ and Cbln2 Pro-lacZ transgenic lines exhibited no 158 detectable LacZ histochemical staining (0 of 10 founders) in the developing cortex between 17 159 and 18 PCD (approximately equivalent to early mid-fetal cortical development in humans), 50% 160 of Cbln2 E2-lacZ transgenics (3 of 6 founders) showed lacZ expression in the brain at this age, 161 recapitulating endogenous frontal cortex-enriched Cbln2 expression ( Fig. 1d) . These findings 162 indicate that Cbln2 E2 is an enhancer that drives expression in the mouse neonatal frontal 163 cortex, including the medially located PFC areas (mPFC). 164
Given the presence of the CBLN2 E2 locus in human, macaque and mouse, we 165 hypothesized that sequence differences between the orthologs may underlie the species-166 specific expression pattern of CBLN2. Comparative genomic and phylogenetic analysis 167 identified three separate deletions (122 bp, 20 bp and 84 bp) in the sequence of the human 168 CBLN2 E2 ortholog as compared to the sequence of the mouse Cbln2 E2 ( Fig. 2a) . Further 169 comparison across multiple vertebrates revealed that two of the three deleted sequences are 170 jointly absent only in extant members of the Hominini clade (i.e., human, common chimpanzee, 171 and bonobo) (Extended Data Fig. 3a, 4) . The first two of these sequences, which we named 172
Hominini-specific deletion 1 and 2 (HSD1 and 2, Fig. 2a ), are highly conserved among other 173
analyzed Haplorhini (i.e., gorilla, orangutan, gibbon, macaque, tarsier), Strepsirrhini (i.e., lemur), 174 and mouse ( Fig. 2a, Extended Data Fig. 3, 4) . The third deletion (D3) sequence was detected 175 only in mouse and rat of the species analyzed (Extended Data Fig. 3b, 4) . Interestingly, we did 176 not detect genomic regions orthologous to Cbln2 E2 in analyzed non-placental mammals and 177 non-mammalian chordates, although they do possess the Cbln2 gene (Extended Data Fig. 4) . 178
To understand transcriptional regulation of developmental CBLN2 cortical expression, 179 we performed transcription factor binding site analysis, which identified multiple putative RA 180 receptor RXR/RAR tandem binding sites in CBLN2 E2 (Fig 2a, Extended Data Fig. 3a) . In our 181 accompanying study 35 , we found that RXRG and RARB are upregulated in the mid-fetal frontal 182 lobe and that Cbln2 expression is reduced in the neonatal frontal cortex of mice lacking both 183
Rxrg and Rarb. Consistent with these findings, we found that overexpression of RXRG and 184 RARB activated human, chimpanzee, gorilla, macaque, and mouse orthologs of CBLN2 E2 in 185 in vitro luciferase reporter assays more than expression of either RXRG and RARB individually 186 (Two-tailed Student's t-test: control vector vs. RXRG/RARB: P = 6.0e-9, 7.0e-5, 1.0e-5, 1.6e-187 11, 2.0e-8, for human, chimpanzee, gorilla, macaque, and mouse, respectively; Fig. 2b ; 188 Extended Data Fig. 5a ). These observations are consistent both with our observation of higher 189 frontal lobe expression of Cbln2, Rxrg, and Rarb, and previous reports showing that RXR and 190 RAR receptors exert their effects as heterodimers in the developing and adult brain 43,44 . 191 192 Clade-specific suppression of CBLN2 E2 by SOX5 193 In addition to RA receptors, analysis of binding sites in Cbln2 E2 also identified multiple putative 194 SOX5 binding sites within the enhancer, including three in HSD1 and a fourth in HSD2 ( Fig. 2a,  195 Extended Data Fig. 3b,c) . This is significant both due to the loss of these sites in Hominini and 196 the role of SOX5 as a primarily repressive transcription factor required for specification and 197 development of cortical projection neurons predominantly within deep layers [45] [46] [47] . Of note, we 198 identified additional non-conserved SOX5 binding sites in mouse HSD1 and 2, as well as 199 multiple SOX5 binding sites in the Muroidea specific D3 ( Fig. 2a) . Moreover, we found that 200 mouse Cbln2 E2 activation by RXRG/RARB heterodimer was suppressed by SOX5 in a dose-201 dependent manner, whereas human and chimpanzee CBLN2 E2 showed no significant 202 suppression by SOX5 at the same doses (Two-tailed Student's t-test: RXRG/RARB vs. 203 RXRG/RARB/SOX5: P = 0.0004, P = 0.6, P = 0.7, for mouse, human, chimpanzee respectively; 204 HSD1 and HSD2 in macaque, abolished suppression by SOX5, suggesting that SOX5 212 suppression is primarily mediated by SOX5 binding sites within these HSDs and D3 (Two-tailed 213 Student's t-test: RXRG/RARB vs. RXRG/RARB/SOX5: P = 0.2 and 0.7 for mouse and macaque, 214 respectively; Fig. 2b ). To test for direct in vivo binding, chromatin immunoprecipitation followed 215 by PCR (ChIP-PCR) assays were conducted using the anterior half of the neonatal mouse 216 neocortex, which found that endogenous SOX5 bound Cbln2 E2 but not Cbln2 E1 ( Fig. 2c) . 217
To understand the functional significance of SOX5 repression of Cbln2 E2 in vivo, we 218 next examined Cbln2 cortical expression using the Emx1-Cre transgenic mouse line engineered 219 to achieve cortex-specific Sox5 deletion. As predicted by luciferase assays, the absence of 220 SOX5 protein specifically within the cortex led to ectopic expression of Cbln2 in deeper layers 221 of the neonatal frontal cortex ( Fig. 2d, e, Extended Data Fig. 6a ). There was also an increase 222 and posterior extension of Cbln2 expression in the upper layers ( Fig. 2d,e To test whether human CBLN2 E2 is sufficient to drive a human-like pattern of Cbln2 expression 235 in the mouse neonatal frontal cortex, we generated a mouse line in which the Cbln2 E2 236 enhancer was replaced in situ (i.e., in the orthologous position) with the corresponding human 237 CBLN2 E2 enhancer using the CRISPR-Cas9 genome editing technique (Extended Data Fig.  238   7) . The engineered mice carrying homozygous humanized Cbln2 E2 (hCbln2 E2) in both alleles 239 (Homo sapiens;Homo sapiens, Hs;Hs) were viable and fertile, and the expression of the cortical 240 upper layer specific marker, Cux2, and SOX5 were comparable to homozygous WT Cbln2 E2 241 (Mus musculus;Mus musculus, Mm;Mm) mice ( Fig. 3c) , indicating that genetically humanized 242 hCbln2 E2grossly functions as the mouse ortholog. Neocortical Cbln2 expression at P0 was 243 increased by 21.7% in hCbln2 E2 (Hs;Hs) cortex, as compared to WT mouse Cbln2 E2 244 (Mm;Mm) by quantitative RT-PCR (Two-tailed Student's t-test: WT Cbln2 E2 vs. hCbln2 E2: P 245 = 0.007; Extended Data Fig. 8 ). Analysis of expression by in situ hybridization showed that 246
Cbln2 was also transiently upregulated in both upper and deeper layers of the hCbln2 E2 PFC 247 at 18 PCD and P1, but not at 16 PCD ( Fig. 3a,b ; Extended Data Fig. 9 ). After P1, Cbln2 248 expression extended into the deeper layers of PFC, coinciding with the down-regulation of 249 SOX5 protein expression (Extended Data Fig. 10 ) in both hCbln2 E2and WT Cbln2 E2. 250
Members of the CBLN family have been reported to regulate synapse development and 251 function [21] [22] [23] [24] [25] [26] [27] . Therefore, we hypothesized that a transient increase in Cbln2 expression in the 252 hCbln2 E2 PFC will lead to increased synapse number. Although Cbln2 is primarily expressed 253 by glutamatergic excitatory projection neurons in the mouse mPFC 27 , it can act as an organizer 254 for both excitatory and inhibitory synapses [23] [24] [25] [26] [27] . Thus, we quantified both excitatory and 255 inhibitory synaptic density in the mPFC, primary somatosensory area (SSp), and primary visual 256 (VISp) area using immunostaining for postsynaptic proteins PSD-95/DLG4 and gephyrin, 257 respectively. In E2 Hs;Hs mice, we observed an increase in the density of PSD-95-258 immunopositive excitatory postsynaptic puncta in both upper (39.5%, BCL11B-259 immunonegative; two-tailed Student's t-test: WT Cbln2 E2 vs. hCbln2 E2: P = 0.0004; N = 5) 260 and deep layers (47.9%, BCL11B-immunopositive; two-tailed Student's t-test: WT Cbln2 E2 vs. 261 hCbln2 E2: P = 0.0001; N = 5) in the mPFC but not in the SSp and VISp, where Cbln2 262 expression is not altered, at P1 ( Fig. 4a,b) . A similar increase in synaptic density in the mPFC 263 was identified in the Sox5 conditional KO mice (58% for upper layers; two-tailed Student's t-264 test: WT Cbln2 E2 vs. hCbln2 E2: P = 2E-5, and 40% for deep layers; two-tailed Student's t-265 test: WT Cbln2 E2 vs. hCbln2 E2: P = 3E-5; N = 3, Fig. 4b) . Similarly, we also observed an 266 increase in the density of gephyrin-immunopositive inhibitory postsynaptic puncta number in 267 both upper (24.2%, BCL11B-immunonegative; Two-tailed Student's t-test: WT Cbln2 E2 vs. 268 hCbln2 E2: P = 0.0002; N = 3) and deep layers (37.9%, BCL11B-immunopositive; two-tailed 269
Student's t-test: WT Cbln2 E2 vs. hCbln2 E2: P = 5E-5; N = 3) at P0 in the hCbln2 E2PFC but 270 not in the SSp and VISp cortex ( Fig. 4c,d WT Cbln2 E2 vs. hCbln2 E2: P = 0.02; 21.4%; N = 3), but not in upper layers (Fig. 4b) , and no 277 significant changes were observed in the density of gephyrin-immunopositive synaptic puncta 278 at this age ( Fig. 4d) . 279 280
Conclusion 281
In this study, we describe a plausible molecular mechanism and underlying genetic basis for 282 anterior to posterior gradient of excitatory synapses, not present in WT at the analyzed ages 308 ( Fig. 4b) . Thus, transient mid-fetal Hominini-specific PFC upregulation of CBLN2 may underlie 309 increased synaptic connectivity in the human PFC. In our accompanying paper 35 , we identified 310 that loss of RA signaling in the developing mouse mPFC leads to both reduced expression of 311
Cbln2, as well as of its functionally related paralog Cbln1, and reduced density of excitatory 312 synapses. Regulation of Cbln2 E2 by RA receptors, RXRG and RARB, provides a direct link 313 between these two finding, and may be part of a more complex gene regulatory network 314 regulating development and adaptive changes in PFC connectivity. 315
While CBLN2 has been implicated in Tourette's syndrome and OCD 37 and mouse 316 CBLN1 is regulated by ASD-and Angelman syndrome-linked UBE3A 53 , they both serve as 317 ligands for multiple NRXNs and GRID1, which are ASD-and schizophrenia-associated proteins, 318 respectively [36] [37] [38] [39] 54 . Multiple lines of evidence have shown that ASD and schizophrenia risk 319 genes, converge in time, brain region, cell type and cell compartment with strong evidence for 320 convergence in synapses 38,39 as well as glutamatergic projection neurons and frontal cortex 321 during human mid-fetal development 36,55-58 . Consistent with these findings, alterations in the 322 levels of some synaptic proteins, the number of synapses, and the amount of connectivity within 323 frontal lobe have been described as the possible underlying pathophysiology of both ASD and 324 schizophrenia 59,60 with dysfunction in the NXRN-GRID trans-synaptic complex, which includes 325 CBLNs, being a putative mechanism and target for interventions. Supplementary Table 1 . 529 530 Generation of transgenic mouse. Cbln2 E2 and its related fragments were PCR-amplified 531 from mouse genomic DNA and ligated into pBgn-lacZ 62 . Vector was linearized with BglII and 532 KpnI and purified by gel separation followed by phenol/chloroform extraction. Transgene 533 fragment was diluted into microinjection buffer (5 mM Tris-HCl, 0.1 mM EDTA), and injected 534 into the pronucleus of FVB mouse fertilized eggs. Transgenic mice were screened for the 535 presence of transgenes by PCR using the lacZ primer set listed in Supplementary Table 1 . 536 537 Generation of humanized Cbln2 E2 mouse. The overall strategy for the generation of 538 humanized Cbln2 E2 (hCbln2 E2) follows a previously described protocol 63 . The targeting 539 vector carrying hCbln2 E2 mouse was constructed as follows: mouse genomic DNA fragments 540 of 1601 bp (chr18: 86721709-86723309, GRCm38/mm10) and 1909 bp (chr18: 86724521-541 86726429, GRCm38/mm10) flanking the region containing Cbln2 E2 (chr18: 86723310-542 86724520, GRCm38/mm10) were PCR-amplified as left and right arm, respectively, using 543 mouse genomic DNA as template. An 852 bp fragment containing human CBLN2 E2 (chr18: 544 72530473-72531324, GRCh38/hg38) was PCR-amplified using human genomic DNA as a 545 template. These three DNA fragments were ligated into XhoI, HindIII and ClaI sites of the PL451 546 vector 64 . For the construction of the templates of guidance RNA, two sets of top and bottom 547 strand oligomers (see Supplementary Table 1 ) directing the double strand break at mouse left 548 and right arm were annealed and ligated into BbsI site of pX330 vector 65 . After amplification of 549 insert with T7-tagged primers (see Supplementary Table 1) Quantification of fold change between human and macaque PFC and non-PFC CBLN2 705 expression for periods 4-6, 7-10 and 11-14 (Student's t-test; ***P = 2.2E-16, **P < 2E-9, *P = 706 3E-5) shown above plots. 2). CBLN4 was both upregulated in the mid-fetal human PFC, compared to macaque PFC 859 (Periods 4-6; Student's t-test, 3.51-fold change, P = 1.5e-8), and compared to human non-PFC 860 areas (Periods 4-6; Student's t-test, 1.37-fold change, P = 0.002). CBLN3 was lowly expressed 861 in both human and macaque mid-fetal PFC. Abbreviations were as described in Fig. 1 information about presence of the CBLN2/Cbln2 gene and CBLN2 E2/Cbln2 E2. The last three 886 columns describe the presence of HSD 1,2, and D3. Deletion of HSD1/2 is specific to humans 887 and chimpanzees (i.e., common chimpanzee and pygmy chimpanzee or bonobo) grouped as 888
Hominini. The mouse E2 sequence was searched in each most updated animal genome 889 browser at UCSC genome browser (as of December 22, 2019). E2 conservation criteria are: 1) 890 identity over 80%; and 2) alignment length over 600 bp as compared with mouse E2 (1005 bp). 891 Extended Data Figure 6 . Cbln2 expression is upregulated in Sox5 conditional knockouts 916
and Cbln2 E2 5' fragment transgenic lines. a, Cbln2 expression is upregulated in Sox5 917 conditional knockout brain at P0. Additional two replicates (Repl #2 and 3) not shown in Figure  918 2d are shown. Scale bar: 200 µm. b, Constructs used for luciferase assay and generation of 919 transgenic animals. c, Luciferase assay for Cbln2 E2 and Cbln2 E2-Fr1. Cbln2 E2-Fr1 reporter 920 was activated by RXRG and RARB, but not suppressed by SOX5. Two-tailed Student's test; 921 **P < 0.005, ***P = 0.00016; NS, not significant; Error bars: S.E.M.; N = 3 per condition. d, 922
Transgenic mouse brain at 17 PCD carrying Cbln2 E2 (N = 3) or Cbln2 E2 Fr1-lacZ reporters 923 (N = 3). Cbln2 expression in the PFC is indicated by arrowheads. Endogenous Cbln2 expression 924 is also shown for comparison (N = 4). Scale bar: 200 µm. 925 
